Jill Dudebout

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

Bhella S, Agbayani G, Hueniken K, Vijenthira A, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Hosseini-Moghaddam SM

Chemotherapy alone vs. chemotherapy plus radiotherapy in female adolescent and young adults with Hodgkin’s lymphoma: reproductive health outcomes

Susan Luong, Claire Mockler, Jessica Pudwell, Wenbin Li, Jill J. Dudebout, Maria P. Vélez

A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE

Transfusion Camp: a prospective evaluation of a transfusion education program for multispecialty postgraduate trainees

Lin Y, Tilokee E, Chargé S, Alam A, Cserti‐Gazdewich C, Lau W, Lee C, Lieberman L, Nixon P, Owens W

Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry

[18F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study

Ur Metser, Jill J. Dudebout, Tara D. Baetz, David C. Hodgson, Deanna L. Langer, Pamela MacCrostie, Victor C. Y. Mak, Noam Tau